Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial

Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T02:18:32.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T18:03:09.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T07:57:23.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:40:07.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:42:27.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of a new study on Soft Tissue Sarcoma, with a focus on the collaboration with Merck Sharp & Dohme LLC and a revision update. Key details about the study's objectives and inclusion criteria have been removed, which may impact the understanding of the study's purpose.
    Difference
    45%
    Check dated 2025-04-16T01:23:18.000Z thumbnail image

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.